<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735213</url>
  </required_header>
  <id_info>
    <org_study_id>Y-2016005</org_study_id>
    <nct_id>NCT02735213</nct_id>
  </id_info>
  <brief_title>Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy</brief_title>
  <official_title>A Prospective Non-inferiority Study of the Use of Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Eye Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Eye Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe whether micropulse laser (MPL) is noninferiority to
      traditional laser therapy in central serous chorioretinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central serous chorioretinopathy (CSC) is characterized by serous detachment of neurosensory
      retina which can cause lose in visual acuity. Some studies have shown that traditional laser
      treatment (TLT) is effective on CSC, although accompanied with side-effects, such as scar.
      Recent retrospective studies suggest micropulse laser (MPL) therapy may also be effective
      without obvious complications in this disease. But to date, there is no study on
      effectiveness of CSC between TLT and MPL.

      The study is the first prospective randomized controlled trial about 577nm micropulse laser
      versus traditional laser treatment in central serous chorioretinopathy. It is a
      noninferiority study. The investigators hypothesize that application of 577nm micropulse
      laser in patients with CSC will prompt resolution of CSC as measured by ocular coherence
      tomography and best corrected visual acuity.This will be a pilot study to establish sound
      methods and provide some insights to the safety and efficacy of CSC treatment. The primary
      outcome measures is the change of BCVA in 12 week.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>12 week</time_frame>
    <description>ETDRS BCVA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the number of patients without any subretinal fluid (SRF)</measure>
    <time_frame>3 week, 7 week, 12 week</time_frame>
    <description>SRF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the central retinal thickness (CRT)</measure>
    <time_frame>3 week, 7 week, 12 week</time_frame>
    <description>CRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laser scar in area lasered on</measure>
    <time_frame>12 week</time_frame>
    <description>colour image and OCT infared image</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of patients need retreatment</measure>
    <time_frame>12 week</time_frame>
    <description>PRN (pro re nata), only for SRF not completely absorbed and CRT &gt;=250um</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Central Serous Choroidopathy</condition>
  <arm_group>
    <arm_group_label>577-MPL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>577nm subthreshold micropulse laser(577-MPL) will be performed on the areas identified on hyperfluorescent &quot;hot spots&quot; on the mid-phase (3 minutes) fluorescein. Multiple laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT&gt;= 250um.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional laser will be performed of the areas identified on hyperfluorescent &quot;hot spots&quot; on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT&gt;= 250um.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>577-MPL</intervention_name>
    <description>9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250~400 milliWatts of power(50% threshold power),150~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.</description>
    <arm_group_label>577-MPL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TLT</intervention_name>
    <description>contimuous wave,100um spot size, 0.05 seconds duration, 55~60 milliwatts of power, 18~27 spots,the laser area is the corresponding leakage on mid-phase FA.</description>
    <arm_group_label>TLT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with CSC；

          2. age&gt;=18 years old;

          3. Duration is less than 6 months；

          4. the presence of subretinal fluid(SRF) involving the macula and detected by use of
             optical coherence tomography (OCT), and CRT&gt;=250um;

          5. active leakage located at ring 2 and ring 3 (ETDRS rings) on fluorescein angiography
             (FA).

        Exclusion Criteria:

          1. Patients with no case of CSC；

          2. Patients with other macular comorbidities including but not limited to diabetic
             retinopathy, macular degeneration；

          3. Patients with prior retinal treatment less than 3 months；

          4. Inability to obtain photographs or to perform FA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Huang</last_name>
    <phone>86-577-88068855</phone>
    <email>wzhuangying@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The eye of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Huang</last_name>
      <phone>86-577-88068855</phone>
      <email>wzhuangying@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoling Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2015 Dec 22;(12):CD011841. doi: 10.1002/14651858.CD011841.pub2. Review.</citation>
    <PMID>26691378</PMID>
  </reference>
  <reference>
    <citation>Iacono P, Battaglia Parodi M, Falcomatà B, Bandello F. Central Serous Chorioretinopathy Treatments: A Mini Review. Ophthalmic Res. 2015;55(2):76-83. doi: 10.1159/000441502. Epub 2015 Dec 1. Review.</citation>
    <PMID>26619293</PMID>
  </reference>
  <reference>
    <citation>Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015 Sep;48:82-118. doi: 10.1016/j.preteyeres.2015.05.003. Epub 2015 May 27. Review.</citation>
    <PMID>26026923</PMID>
  </reference>
  <reference>
    <citation>Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002 Feb;22(1):19-24.</citation>
    <PMID>11884873</PMID>
  </reference>
  <reference>
    <citation>Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988 Nov;72(11):829-34.</citation>
    <PMID>3061449</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Eye Hospital of Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Xiaoling Liu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Central Serous Choroidopathy</keyword>
  <keyword>Micropulse Laser Treatment</keyword>
  <keyword>Traditional laser Treatment</keyword>
  <keyword>optical coherence tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
    <mesh_term>Choroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

